NCT02130453CompletedPhase 4
Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking
Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging
Source: ClinicalTrials.gov · Last updated 2 Oct 2024
Brief summary (registry, in English)
The goal of this clinical research study is to compare regadenoson nuclear stress testing with echocardiography strain measurements (an ultrasound imaging method that measures hearts function) in detecting coronary artery disease.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 161 (actual)
- First submitted
- 1 May 2014
- Start date
- 30 Sept 2014
- Primary completion date
- 28 Jun 2024
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Coronary artery disease
- NCT number
- NCT02130453
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 161
- From 30 Sept 2014 to the primary completion date, 28 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with allergy to regadenoson.
Other
- Patients consented for the trial that on the baseline 2D study have poor acoustic echo windows (i.e. a reader is unable to see in definition 2 or more segments from the apical views) will not be eligible to continue in the trial and peak hyperemia images will not be obtained.
- Any patient with tachycardia defined as HR of 100 or higher at the day of SPECT will not be eligible for this study.
- Second- or third- degree AV block.
- Sinus node dysfunction.
- Patients with LBBB and/or artificial pacemaker.
Who the study is looking for
- Cancer patients who are scheduled for (perfusion) nuclear stress testing using regadenoson as stress agent.
- Indications for stress testing is either: -as part of a pre-operative evaluation prior to a planned cancer related surgery that is considered to be at least of intermediate risk (Intra-peritoneal, intra-thoracic, head and neck surgery, orthopedic or prostate surgery) OR -as an evaluation in the cardiology clinic for symptoms described in a cardiology consult as typical angina, or of significant suspicion for coronary disease or symptoms described as likely of a cardiac/coronary etiology.
- Patients with a history of LV dysfunction will be still candidates for enrollment in the study if they have documented LVEF recovery (most recent documented LVEF of 50% or higher) for at least 6 months prior to SPECT regardless of current cardiac medication regimen.
- Age 18 - 80 years.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas - MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.